Researchers have developed a novel synthetic protein to treat macular degeneration and other incurable eye diseases that lead to blindness in millions of people. It is the first drug of its kind and is currently in human trials. Neovascular age-related macular degeneration (AMD) affects more than 200 million people worldwide. In addition, millions more with type-1 or type-2 diabetes are at risk of developing diabetic macular edema (DME). Both diseases currently have no cure. The novel an...